Real-time analysis of gene expression in experimental tumor models represents a major tool to document disease biology and evaluate disease treatment. However, monitoring gene regulation in vivo still is an emerging field, and thus far it has not been linked to long-term tumor growth and disease outcome. In this report, we describe the development and validation of a fluorescence-based gene expression model driven by the promoter of the cyclindependent kinase inhibitor p21 waf1,cip1 . The latter is a key regulator of tumor cell proliferation and a major determinant in the response to many anticancer agents such as histone deacetylase inhibitors. In response to histone deacetylase inhibitors, induction of fluorescence in A2780 ovarian tumors could be monitored in living mice in a noninvasive real-time manner using whole-body imaging. Single p.o. administration of the histone deacetylase inhibitor MS-275 significantly induces tumor fluorescence in a time-and dose-dependent manner, which accurately predicted long-term antitumoral efficacy in individual mice following extended treatment. These findings illustrate that this technology allows monitoring of the biological response induced by treatment with histone deacetylase inhibitors. In addition to providing experimental pharmacokinetic/pharmacodynamic markers for investigational drugs, this model provides insight into the kinetics of in vivo regulation of transcription, which plays a key role in causing and maintaining the uncontrolled proliferation of tumor tissue. [Mol Cancer Ther 2006;5(9):2317 -23] 
Introduction
Transcriptional regulators are frequently altered in tumors and play a causal role in maintaining malignant phenotype (1) . A well-known example is the tumor suppressor p53, which controls cellular response to radiation and chemotherapeutic agents and is inactivated in the majority of human tumors (2, 3) . One of the main target genes of p53 is the cyclin-dependent kinase inhibitor p21
waf1,cip1 , which is crucial for G 1 checkpoint control and for maintaining the G 2 checkpoint in response to DNA damage (4 -7) . In addition, p21
waf1,cip1 protein plays an important role in cell senescence and differentiation (8) . p21 waf1,cip1 is highly regulated at the transcriptional level and its expression is induced by a broad panel of upstream signaling pathways. p53 activates p21
waf1,cip1 transcription through direct binding to Sp1, a constitutive transcriptional activator that binds to the GC-boxes in the proximal region of the p21 waf1,cip1 promoter. p53 binding results in the dissociation of histone deacetylase 1 (HDAC1), which is responsible for the constitutive suppression of the p21 waf1,cip1 gene (9) . Histone deacetylase -induced transcriptional silencing is a key process in tumor growth (10) and several histone deacetylase inhibitors have shown promising activity in early clinical development (11) .
As p21 waf1,cip1 is regulated by a large number of signaling pathways and is also a key determinant in the biological outcome after triggering these signaling pathways, an experimental model visualizing p21
waf1,cip1 gene expression in a real-time manner would be of value in predicting the long-term antitumor effect of investigational agents. In addition, such a model would allow rapid identification of novel antineoplastic agents in general, a process that is currently hampered by the limited throughput of mouse xenograft tumor studies, requiring long-term studies and the necessity for extensive compound synthesis. For this reason, many promising early compounds are not evaluated in vivo and potentially numerous promising new therapeutic agents are abandoned.
We have developed an experimental tumor model that allows noninvasive real-time analysis of signal transduction and gene expression in nude mice bearing human xenografts using whole-body imaging technology (12) . Human A2780 ovarian carcinoma cells have been engineered with a reporter gene construct encoding the fluorescent ZsGreen protein, of which the expression is under the control of the p21 waf1,cip1 promoter. When s.c. grafted to athymic nude mice, A2780-p21 waf1,cip1 ZsGreen ovarian xenografts allow noninvasive real-time imaging of gene expression regulation in living tumor-bearing mice. ZsGreen fluorescence fully parallels regulation of the endogenous p21 waf1,cip1 protein, and induction of fluorescence in vivo was found to accurately predict long-term antitumor activity of the HDAC inhibitor MS-275 in individual mice. Induction of the p21 waf1,cip1 promoter in vivo was observed in both the center and periphery of the experimental tumors, indicating an exposure and biological response in the entire tumor. Our data therefore show that this model allows the analysis of the mechanism of action of a selected drug in vivo and noninvasive real-time evaluation of the pharmacodynamic response to HDAC inhibitors in animal models.
Materials and Methods

Materials
Human A2780 ovarian carcinoma cells (American Type Culture Collection, Manassas, VA) were maintained as monolayers in RPMI 1640 supplemented with 10% FCS, 2 mmol/L L-glutamine, and gentamicin at 37jC in a humidified 5% CO 2 incubator. All cell culture reagents were purchased from Life Technologies, Inc. (Gaithersburg, MD). Trichostatin A was obtained from Calbiochem (San Diego, CA). Cell proliferation was measured by a classic 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide assay (Serva, Heidelberg, Germany).
Production of the 1,300-kb p21 waf1,cip1 PromoterZsGreen Construct
To generate an HDAC inhibitor -responsive p21
waf1,cip1
promoter construct, genomic DNA was extracted from A2780 cells and used as template for nested PCR isolation of a 1.3-kb fragment containing the À1,300 to +88 region of the p21 waf1,cip1 promoter relative to the TATA box. The first amplification was done with the oligonucleotide pair GAGGGCGCGGTGCTTGG and TGCCGCCGCTCTCT-CACC. The resulting 4.5-kb fragment was reamplified with the oligos TCGGGTACCGAGGGCGCGGTGCTTGG and ATACTCGAGTGCCGCCGCTCTCTCACC and subsequently with the oligos TCGGGTACCGGTAGATGG-GAGCGGATAGACACATC and ATACTCGAGTGCCGC-CGCTCTCTCACC. The luciferase reporter was removed from the pGL3-basic plasmid (Promega, Leiden, the Netherlands) and replaced by the ZsGreen reporter (pZsGreen1-N1 plasmid, Clontech, Mountain View, CA) at KpnI and XbaI restriction sites. pGL3-basic-ZsGreen-1300 was constructed via insertion of the above-mentioned 1.3-kb fragment of the human p21 waf1,cip1 promoter region into pGL3-basic-ZsGreen at the XhoI and KpnI sites. All restriction enzymes were purchased from Boehringer Mannheim (Mannheim, Germany).
Generation of Stable Cell Lines A2780 cells were seeded at a density of 2 Â 10 5 per 10-cm diameter cell culture dish, grown for 24 hours, and transfected with 2 Ag of pGL3-basic-ZsGreen-1300 and 0.2 Ag of pSV2neo resistance vector using Lipofectamine 2000 (Invitrogen, Brussels, Belgium). Single-cell clones were obtained in medium containing G418 (450 Ag/mL) and tested for detectable basal level of fluorescence to allow for detection of tumor mass in the absence of stimulation. All further studies were done with A2780-p21 waf1,cip1 ZsGreen clone 5 (A2780-p21 waf1,cip1 ZsGreen). Subcutaneous. fluorescent tumors could be detected through the skin of nude mice and measured using an automated whole-body imaging system (12) . From day 12, mice were treated p.o. once daily for 1, 2, 3, or 4 days with solvent or the indicated dose of MS-275 (10 animals per group). Tumors were evaluated for fluorescence by the automated whole-body imaging system [fluorescent stereomicroscope type Olympus SZX12 equipped with a green fluorescence filter and coupled to a CCD camera type JAI CV-M90 controlled by a software package based on the IMAQ Vision Software from National Instruments (Austin, TX)]. Median and average value of tumor fluorescence were calculated by locating the tumor by creating a graylevel image followed by calculating a binary image. The light intensity of all pixels within this area was normalized between 0 (black) and 1 (white). Median light intensity of the tumor was normalized for tumor area.
Fluorescence Microscopy To evaluate the distribution of ZsGreen protein expression, A2780-p21 waf1,cip1 ZsGreen tumors were excised, mounted in Peel-A-Way molds (Polysciences, Warrington, PA) with optimum cutting temperature (Sakura, Torrance, CA), and then frozen in liquid nitrogen. Cryosections of 10-Am thickness were mounted on glass slides and air-dried for 30 minutes at room temperature. Within 1 hour after drying, ZsGreen fluorescence was evaluated with an Axioplan 2 (Zeiss) equipped with Epiplan-Neofluar objectives and an Axiocam camera. Images taken with the Axiocam camera from peripheral and central areas of tumor sections from control and treated groups were stored as TIF files and imported in LSM-510 software (Zeiss). To enhance visualization of the distribution of the ZsGreen protein, the imported TIF files were viewed as pseudo three-dimensional pixel intensity maps. For three-dimensional colocalization with tumor vasculature, tumors were collected by transcardial perfusion fixation with 4% paraformaldehyde. Actin and endothelium of blood vessels were visualized by Bodipy 558/568 phalloidin staining and CD-31 (Cy3) immunofluorescent labeling, respectively. Mounted samples were observed with the LSM510 laser scanning microscope.
In vivo Antitumoral Studies MS-275 was synthesized in-house and formulated at 1 mg/mL in 20% hydroxypropyl-h-cyclodextrin (final pH 8. promoter fragment (À1,300 to +88 bp) regulating the expression of ZsGreen fluorescent protein (see Materials and Methods). This promoter region contains key cis-acting elements that are required for p21 waf1,cip1 regulation, including Sp1 sites that mediate its activation by HDAC inhibitors (13, 14) .
To validate this engineered cell model, ZsGreen protein expression, and therefore fluorescence signal, needs to reflect the regulation of endogenous p21
waf1,cip1 in cellbased assays. To study p21
waf1,cip1 transcriptional regulation, we employed HDAC inhibition, which results in derepression of the p21 waf1,cip1 promoter, thereby causing cycle arrest (15) . As illustrated in Fig. 1 , the majority of the A2780-p21
waf1,cip1 ZsGreen cell population has a low basal fluorescence (i.e., below 10 2 relative fluorescence units). The HDAC inhibitor trichostatin A strongly increased median fluorescence to >10 3 waf1,cip1 protein induction by these agents in A2780-p21 waf1,cip1 ZsGreen cells (Fig. 2B) . Again, LAQ-824 and trichostatin A were most potent at 0.3 and 1 Amol/ L, respectively, and induced p21 waf1,cip1 protein levels to a comparable extent as the observed increase in ZsGreen fluorescence (5.5-and 5.7-fold, respectively). SAHA and MS-275 maximally induced endogenous p21 waf1,cip1 protein expression at 10 Amol/L (4.1-and 6.1-fold, respectively). Similar induction of endogenous p21
waf1,cip1 protein expression was observed in parental nontransfected A2780 cells (data not shown). The decrease in fluorescence and waf1,cip1 protein levels at higher doses was due to cell death. The potency of these agents vis-à-vis p21 waf1,cip1
induction was paralleled by their antiproliferative activity as illustrated in Fig. 2C . Cell proliferation after 4 days was inhibited with IC 50 values of 4.2 and 3.4 Amol/L for SAHA and MS-275, respectively, which is a similar potency at which an induction of p21 waf1,cip1 and ZsGreen protein expression was observed after 24 hours. LAQ-824 and trichostatin A inhibited cell proliferation at 0.15 and 0.21 Amol/L (IC 50 ), respectively, whereas ZsGreen protein was induced at 0.3 and 1 Amol/L, respectively. Summarized, these data reveal that fluorescence induction in A2780-p21 waf1,cip1 ZsGreen cells predicts the antiproliferative potency of HDAC inhibitors in cell-based assays.
HDAC Inhibitors Induce Fluorescence in A2780-p21
ZsGreen Xenografts in Nude Mice To investigate whether the p21
waf1,cip1 ZsGreen model could be used to monitor the biological effect of HDAC inhibitors in tumor-bearing mice, studies were done with MS-275. Previous work had shown that MS-275 inhibits A2780-p21 waf1,cip1 ZsGreen tumor growth when cells were grafted s.c. in immunodeficient mice (data not shown). In those studies, mice were treated p.o. with increasing doses of MS-275 once daily for 21 days starting 4 days after injection of cells. At the maximum tolerated dose (20 mpk), tumor growth was inhibited by 83% whereas treatment at 10 mpk resulted in 58% inhibition. Tumor growth inhibition was statistically significant starting on day 14 at both doses, and on day 24 the inhibition of tumor growth at 20 mpk was significantly higher compared with 10 mpk (P < 0.05). At 5 mpk, tumor inhibition on day 24 was marginal (31% inhibition; P = 0.08, one sided), whereas 2.5 mpk was an inactive dose.
As shown in Fig. 3 , MS-275 at biologically active nontoxic doses (i.e., 5, 10, and 20 mpk) clearly induced tumor fluorescence in vivo (Fig. 3A) . Time course analysis of this induction using automated whole-body imaging of tumorbearing living animals revealed that a significant induction of fluorescence in the tumor could be detected already after one single administration of MS-275 (Fig. 3B) . Dosing at 5, 10, and 20 mpk resulted in a significant increase (P < 0.05) in median fluorescence from 0.25 to 0.57, 0.63, and 0.75 absorbance units, respectively. Median fluorescence intensity did not alter at the 5-and 10-mpk dose when treating the mice for 2 or 3 subsequent days. In contrast, at the most active dose (20 mpk), a strong increase in the extent of fluorescence was observed when comparing dosing once (0.75 absorbance unit) with dosing for 2 and 3 days (Fig. 3C,  1.01 and 2.44 absorbance units, respectively) . The observed increased p21
waf1,cip1 promoter activity, when comparing dosing once to dosing for 3 consecutive days, was statistically significant with the Wilcoxon-Mann-Whitney test (P < 0.05). These data illustrate that whole-body imaging allows the monitoring of biological responses in the tumor as a function of time. Because a significant response was observed at biologically active (antitumor) doses only (i.e., not at 2.5 mpk; Fig. 3B ) and the extent of the response paralleled the known antitumor efficacy of MS-275, this suggested that the p21 waf1,cip1 ZsGreen tumor model can be used to evaluate HDAC inhibitor activity in vivo in a short time frame (a few days compared with a few weeks for classic antitumor studies).
When doing long-term in vivo studies with antitumor agents, a large variation in the biological response of individual mice is generally observed, requiring the use of large numbers of animals. Because significant variability was also found in the short-term induction of p21 waf1,cip1 -ZsGreen, we sought to investigate whether ZsGreen fluorescence correlated with tumor growth for individual mice. As illustrated in Fig. 4 , mice showing high tumor fluorescence also had a relatively low final tumor weight, whereas poor responders (e.g., in the 10-and 15-mpk treatment groups) had higher final tumor weights. In summary, this shows that the p21 waf1,cip1 -ZsGreen fluorescence induction in tumors predicts the extent of response to the treatment with the HDAC inhibitor MS-275 in individual mice.
Localized Response to HDAC Inhibitors within A2780 Tumor Tissue In vivo
In addition to predicting long-term antitumor activity, the p21
waf1,cip1 ZsGreen model may also be of value to study the distribution of the biological response within the tumor tissue. To evaluate the tissue distribution of the response to MS-275, a more detailed analysis of the fluorescent signal distribution pattern was done using 
Real-time Analysis of Gene Expression in Tumors
fluorescence analysis of tumor cryosections. A distinct difference in expression of ZsGreen was observed. Fluorescence was much stronger in treated tumors than in controls (Fig. 5) . On control samples, only a few areas of high fluorescence intensity were observed ( Fig. 5A and C) . In treated tumors, ZsGreen-fluorescence was not uniform throughout the tissue. Generally, focal spots of high fluorescence were surrounded by areas with weaker intensity. The areas of these high intensity spots contained from a few cells to hundreds of cells and were found not to colocalize with tumor vasculature. Analysis of sections stained for h-actin showed that ZsGreen-labeling was localized in the cytoplasm of the tumor cells (Supplementary Fig. S6 ). 5 There was no difference in fluorescence between the peripheral and central parts of the tumor (Fig. 5B and D) , indicating exposure of the drug and/or a biological response throughout the entire tumor.
Discussion
Technologies that allow real-time molecular imaging of gene expression offer the potential for increasing our understanding of disease biology, evaluating disease treatment in vivo, and visualizing the effects of drugs at the cellular level in living animals (16) . This report shows that A2780-p21 waf1,cip1 ZsGreen ovarian xenografts allow noninvasive real-time assessment of the regulation of gene expression in living tumor-bearing mice. ZsGreen fluorescence fully parallels regulation of the endogenous p21 waf1,cip1 protein, and induction of fluorescence in vivo accurately predicted the long-term antitumoral activity of HDAC inhibitors in individual mice. Because p21 waf1,cip1 is commonly regulated by anticancer agents, such as azacytidine, taxanes, anthracyclins, and cisplatin, this model is not limited to the evaluation of HDAC inhibitors but has broader application. Finally, induction of p21 waf1,cip1 promoter activity in vivo was observed in both the central and peripheral regions of the treated tumors, indicating a biological response in the entire tumor.
Although whole-body imaging of highly fluorescent xenografts is commonly used to monitor tumor growth over time (17) , real-time monitoring of gene regulation in vivo in response to pharmaceutical agents represents an emerging field. Noninvasive in vivo imaging has been described for a number of signal transduction processes such as protease activity, protein-protein interactions, and protein degradation (18 -21) . For example, Bremer and Tung (18) described visualization of the inhibition of matrix metalloproteinase protease activity in intact tumor-bearing mice with Prinomastat (AG3340). This involved the delivery of fluorescent probes of which the properties change after being bound or cleaved, such as in the case of fluorescence recovery after photobleaching (22) and imaging using autoquenched near-IR fluorescence (23) . In vivo analysis of protein degradation was shown by Luker et al. (20) by monitoring overall proteasome activity by imaging turnover of a labile luciferase protein, whereas Zhang et al. (21) monitored cyclin-dependent kinase-2 activity in vivo by imaging the turnover of a p27-luciferase fusion protein.
Recently, Qian et al. (24) described reactivation of the retinoic acid receptor h2 promoter by MS-275 and retinoids in PC3 prostate xenografts using bioluminescence. However, in all these studies, a link was not established between the signal transduction response and final therapeutic outcome. To monitor real-time gene expression regulation in vivo, fluorescent protein expression was used as a reporter because of its compatibility with unanesthesized animals and because it does not require the delivery of a substrate to the tumor before imaging. This second aspect is important when studying in vivo gene responses to pharmaceutical agents because a substrate may nonspecifically modulate gene expression or might interfere with the pharmacokinetics or pharmacodynamics of the investigational drug (16) . This issue is illustrated by the work of Doubrovin et al. (25) . The enzyme herpes simplex virus-1 thymidine kinase was expressed under the control of a p53-responsive element, enabling positron emission tomography imaging of gene expression after administration of the thymidine kinase substrate . In addition to the risk of changing pharmacokinetic properties when coadministrating both an activator of signal transduction and a positron emission tomography substrate, the radioactive substrates needed for positron emission tomography technology may potentially also induce DNA damage/stress pathways and thereby activate p53 signaling. These data clearly illustrate the importance of nonsubstrate dependent assays when evaluating antitumoral therapeutic agents. These drawbacks were circumvented by engineering the stable A2780 ovarian carcinoma cell line in which the p21 waf1,cip1
promoter (À1,300 to +88 bp) regulates the expression of ZsGreen fluorescence.
In this article, we have used HDAC inhibitors to induce the expression of the cyclin-dependent kinase inhibitor p21 waf1,cip1 . A causal relationship between this p21
up-regulation and the antiproliferative effects of HDAC inhibitors has previously been established by studies showing that p21 waf1,cip1 -deficient HCT-116 human colon carcinoma cells have increased resistance to these agents (15, 26) . HDAC inhibitors activate p21
waf1,cip1 gene expression by dissociating the HDAC repressor complex from the transcriptional activator Sp1, which drives p21
transcriptional activity. ZsGreen fluorescence was found to fully parallel the regulation of the endogenous p21 waf1,cip1 protein by a panel of HDAC inhibitors in vitro. This is in agreement with other reports showing that trichostatin A, MS-275, and SAHA induce transactivation of the murine p21 waf1,cip1 promoter through the Sp1 sites located within the À166 to +40 bp region relative to the TATA box (12, 14) , a region contained within our p21 waf1,cip1 À1,300 to +88 bp promoter construct. In agreement with the key role of p21 waf1,cip1 in the antitumor effects of many neoplastic agents, induction of p21 waf1,cip1
promoter -driven fluorescence in vivo was found to properly predict the long-term antitumor activity of anticancer agents. Furthermore, kinetic analysis of the fluorescence after several days of dosing indicated accumulation of response after 3 days of dosing for MS-275 at 20 mpk, but not at 10 mpk. This is in agreement with the higher antitumor activity of this agent at 20 mpk. Such a cumulative effect at higher doses may point to accumulation of the compound in tumor tissue over time or changed pharmacokinetic behavior of the agent after repeated dosing. Although the pharmacokinetic profile of MS-275 in mice is not known, early data from clinical trials in human show a long half-life for this agent (29.9 hours) and an increase in exposure at the second dose in four of six patients (27) . Interestingly, the fluorescence response was found to be predictive for tumor growth in individual mice. Typically, the response of individual animals to neoplastic agents shows a high variability, which is why large numbers of animals are used for each dose group in this kind of study. Pharmacokinetic analysis showed comparable levels of drug in the tumor tissue between individual animals. Therefore, our data indicate that the high interindividual variation in tumor growth inhibition is dictated by the absence of the biological response to these agents and is not due to lack of activation of HDAC regulated genes.
In summary, our data indicate that the p21 waf1,cip1
promoter fluorescent xenografts provide a powerful tool that allows rapid assessment of in vivo antitumoral activity. This facilitates earlier evaluation of the compounds in the drug discovery process without the need for time-and reagent-consuming pharmacokinetic/pharmacodynamic studies, thereby accelerating significantly the discovery and development of novel antitumor agents.
